Immediate versus gradual TocilizuMab discontinuAtion in GIant Cell Arteritis: protocol of the multicentre randomised open-label MAGICA trial
Introduction Giant cell arteritis (GCA) is a large-vessel vasculitis occurring in people aged over 50 years. Recent studies have shown that tocilizumab (TCZ), an anti-IL-6 receptor monoclonal antibody, is remarkably effective in treating GCA and allows significant dose sparing of glucocorticoids. Ho...
Збережено в:
| Автори: | , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
BMJ Publishing Group
2025-10-01
|
| Серія: | BMJ Open |
| Онлайн доступ: | https://bmjopen.bmj.com/content/15/10/e108115.full |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
